Arca
Skip to content
Tools
Tools

EGLN1: Egl nine homolog 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on EGLN1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Vadadustat

Phase 31

  • Enarodustat

Phase 21

  • Molidustat

Phase 10

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Egl nine homolog 1 inhibitor.
    VadadustatApprovedAkebia TherapeuticsSmall moleculeInhibitor—3Boxed warning
    EnarodustatPhase 3Shenzhen Salubris Pharmaceuticals Co., Ltd.Small moleculeInhibitor—5—
    MolidustatPhase 2BayerSmall moleculeInhibitor—1—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
    Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD PatientsEnarodustat—RecruitingHuashan Hospital2026-08-03
    Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center HemodialysisVadadustatPhase 3Not yet recruitingGeoff Block2026-05-04
    Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAAEnarodustatPhase 3Not yet recruitingPeking Union Medical College Hospital2026-04-23
    Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis PatientsVadadustatPhase 4Not yet recruitingMackay Memorial Hospital2026-04-17
    Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung InjuryVadadustatPhase 2 / Phase 3RecruitingPaul Potnuru2025-07-25
    Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD PatientsEnarodustatPhase 4Not yet recruitingShenzhen Salubris Pharmaceuticals Co., Ltd.2025-07-23
    SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid MalignanciesEnarodustatPhase 2RecruitingShenzhen Salubris Pharmaceuticals Co., Ltd.2024-12-17
    Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney DiseaseEnarodustatPhase 4RecruitingShanghai Zhongshan Hospital2024-12-10
    A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal AnemiaMolidustat—Active, not recruitingBayer2021-05-24

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Erythrocytosis, familial, 3
    0.73
    Anemia
    0.60
    Neurodegenerative disease
    0.48
    Autosomal dominant secondary polycythemia
    0.47
    Chronic renal failure syndrome
    0.37
    Stage 5 chronic kidney disease
    0.33
    Triple-negative breast carcinoma
    0.33
    Kidney disorder
    0.26

    Genes and Related Targets

    Complexes and families that share a gene with this target
    Genes
    EGLN1

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5697, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9GZT9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.